Progyny PGNY 深 滬
等待開盤 09-23 09:30:00 美东时间
26.24
-0.620
-2.31%
華盛通- 最 高27.15
- 今 開26.96
- 成交量 88.20万股
- 最 低 26.155
- 昨 收 26.86
- 總市值 20.13亿
- 52周最高 33.065
- 市盈率 靜 40.29
- 換手率 1.15%
- 52周最低 16.10
- 委 比 73.54%
- 總股本 7672.68万
- 歷史最高 68.32
- 量 比 0.69
- 振 幅 3.70%
- 歷史最低 13.29
- 每 手 1
- 風險率 4.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
Citizens Maintains Market Outperform on Progyny, Raises Price Target to $33
Citizens analyst Constantine Davides maintains Progyny (NASDAQ:PGNY) with a Market Outperform and raises the price target from $31 to $33.
09-08 21:36
Progyny, Inc. to Present at the Wells Fargo Healthcare Conference
Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, announced that its Chief Financial Officer, Mark Livingston, will present at the Wells Fargo 21st Annual Healthcare Conference in Boston on September 8, 2026, at 11:00 a.m. ET. A live audiocast and replay will be available on Progyny’s investor relations website. Progyny empowers patients with comprehensive support, access to specialists, and tools to i...
09-03 15:16
美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
Wells Fargo Initiates Coverage On Progyny with Overweight Rating, Announces Price Target of $37
Wells Fargo analyst Stan Berenshteyn initiates coverage on Progyny (NASDAQ:PGNY) with a Overweight rating and announces Price Target of $37.
08-20 22:08
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
Barclays Maintains Equal-Weight on Progyny, Lowers Price Target to $30
Barclays analyst Peter Warendorf maintains Progyny (NASDAQ:PGNY) with a Equal-Weight and lowers the price target from $34 to $30.
08-12 20:37
美股夜盘 | CEVA Inc大升8.61%，普拉格能源上升4.59%
CEVA Inc大升8.61%；普拉格能源上升4.59%；Applied Optoelectronics, Inc.上升3.58%
08-10 15:01
